All News
Filter News
Found 809,010 articles
-
Starton Successfully Completes Proof of Concept Study for Transdermal Lenalidomide
12/27/2019
Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion of a proof of concept study of multiple myeloma with lenalidomide using a model which emulates transdermal delivery.
-
Shineco, Inc. Receives Extension of Compliance Period from Nasdaq
12/27/2019
Shineco, Inc. ("Shineco" or the "Company"; Nasdaq: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, hemp products, and various health and well-being focused plant-based products in China, announced today that the Company received a letter from Nasdaq Listing Qualifications Staff (“Nasdaq”) that the Company has been granted an additional 180-day grace period or until June 20, 2020
-
Jeanne White-Ginder to Address National Conference 30 Years After Ryan White Program, Named After Her Son, Was Created to Help Those With HIV/AIDS
12/27/2019
HIV/AIDS advocates will join together in Fort Lauderdale on January 6-7, 2020 for the 2nd Ryan White Clinics for 340B’s national conference.
-
Sinovac Announces Approval of Varicella Vaccine for Prevention of Varicella-Zoster Virus (Chickenpox) in Children
12/27/2019
Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company’s varicella vaccine to prevent the varicella-zoster virus in children from 1 to 12 years old.
-
Microbot Medical Inc. Announces Closing of $9.59 Million Registered Direct Offering of Common Stock
12/27/2019
Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase price of $10.50 per share for total gross proceeds of approximately $9.59 million, before deducting placement agent fees and offering expenses.
-
electroCore Announces Board of Directors Transition
12/27/2019
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox, will resign from the Board effective March 31, 2020.
-
Advisory - Health Canada seized unauthorized health products, including 6 prescription skin products that may pose serious health risks from Excel Beauty Supply in the Albion Centre, Etobicoke, Ontario
12/27/2019
Health Canada is advising Canadians that it seized numerous unauthorized health products, including six prescription skin products that may pose serious health risks such as skin deterioration, low or high blood pressure, blisters or scarring from Excel Beauty Supply, located in the Albion Centre, Etobicoke, Ontario.
-
Governor General Announces 120 New Appointments to the Order of Canada
12/27/2019
Her Excellency the Right Honourable Julie Payette, Governor General of Canada, announces 120 new appointments to the Order of Canada.
-
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec. 27, 2019
12/27/2019
Xeris Pharmaceuticals, Inc. announced that on December 24, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 14,500 shares of its common stock to 3 new employees under Xeris’ Inducement Equity Plan.
-
Population Health Strategies Improved Patient Experience & Reduced Hospital Stays for Kids on Medicaid
12/27/2019
Integrated care teams and care management tools led to 3,600 fewer bed days in a year
-
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
12/27/2019
Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations
-
CORRECTION: Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd
12/27/2019
ONCOLOGY PHARMA, INC. is pleased to announce that it has received a letter of intent dated December 20th to facilitate a financing of US$ 38.4 Million from SCP Investment Partners, Ltd, UK.
-
New Major Order From China - Dec. 27, 2019
12/27/2019
Bactiguard has received a new order from Well Lead Medical in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.
-
BioSpace Global Roundup, Dec. 26
12/26/2019
Companies from across the globe provide updates on their business and pipeline progress. -
A closer look at the six jobs in life sciences that are currently in high demand.
-
Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label
12/26/2019
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the product label for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for the treatment of osteoarthritis (OA) knee pain.
-
Amneal Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
12/26/2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15, 2020.
-
Starton Therapeutics: Announcing Name Change for ChemioCare Inc
12/26/2019
ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced it has changed the name of the Company to Starton Therapeutics, Inc.
-
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionTopline results expected in Q1 2020
12/26/2019
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the completion of patient enrollment in its Sulopenem for Resistant Enterobacteriaceae (SURE) 1 clinical trial in uncomplicated urinary tract infections (uUTI).
-
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
12/26/2019
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Xyphos Biosciences, Inc. (CEO: James Knighton, "Xyphos") today announced that Astellas has acquired Xyphos.